U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula Gd
Molecular Weight 157.25
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 3

SHOW SMILES / InChI
Structure of GADOLINIUM CATION (3+)

SMILES

[Gd+3]

InChI

InChIKey=RJOJUSXNYCILHH-UHFFFAOYSA-N
InChI=1S/Gd/q+3

HIDE SMILES / InChI

Molecular Formula Gd
Molecular Weight 157.25
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/7960618; https://www.ncbi.nlm.nih.gov/pubmed/?term=23435930; http://mnoncology.com/disease-drug-info/drug-dictionary/G/

DOTAREM (Gadoterate Meglumine ) is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associatedtissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Gadoterate Meglumine is a gadolinium chelate paramagnetic contrast agent. When placed in a magnetic field, gadoterate meglumine produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because gadobenate dimeglumine is excreted in the bile, it may be used to visualize the biliary system using MRI.

CNS Activity

Curator's Comment: Gadoterate does not cross the intact blood-brain barrier and, therefore, does not enhance normal brain or lesions that have a normal blood-brain barrier, e.g. cysts, mature post-operative scars. However, disruption of the bloodbrain barrier or abnormal vascularity allows distribution of gadoterate in lesions such as neoplasms, abscesses, and infarcts.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P27169
Gene ID: 5444.0
Gene Symbol: PON1
Target Organism: Homo sapiens (Human)
105.0 mM [Ki]
Target ID: P52209
Gene ID: 5226.0
Gene Symbol: PGD
Target Organism: Homo sapiens (Human)
73.0 mM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
DOTAREM

Approved Use

Indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

Launch Date

2013
Diagnostic
GADAVIST

Approved Use

Gadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease.

Launch Date

2011
Diagnostic
GADAVIST

Approved Use

Gadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease.

Launch Date

2011
Diagnostic
GADAVIST

Approved Use

Gadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease.

Launch Date

2011
PubMed

PubMed

TitleDatePubMed
Aluminum is a weak agonist for the calcium-sensing receptor.
1999 May
Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products.
2002 May 15
A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium.
2004 May
Nociceptor and hair cell transducer properties of TRPA1, a channel for pain and hearing.
2005 Apr 20
Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures.
2006 Feb
Metabotropic receptor-activated calcium increases and store-operated calcium influx in mouse Müller cells.
2008 Jul
Renal failure and gadolinium. The number of documented cases is rising.
2008 Oct
Large sample of nephrogenic systemic fibrosis cases from a single institution.
2009 Oct
Differential expression of TRPM2 and TRPV4 channels and their potential role in oxidative stress-induced cell death in organotypic hippocampal culture.
2010 Mar
TRPC5 channel sensitivities to antioxidants and hydroxylated stilbenes.
2011 Feb 18
The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study).
2015 Sep
MRI in multiple sclerosis: an intra-individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T.
2016 Mar
Patents

Sample Use Guides

Recommended dose for adults and pediatric patients (including term neonates) is 0.1 mL/kg body weight. Administer as an intravenous bolus injection. Follow injection with a normal saline flush.
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:24:38 GMT 2023
Edited
by admin
on Fri Dec 15 17:24:38 GMT 2023
Record UNII
AZV954TZ9N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GADOLINIUM CATION (3+)
Common Name English
GADOLINIUM, ION (3+)
Common Name English
GADOLINIUM CATION
Common Name English
GADOLINIUM ION
Common Name English
Classification Tree Code System Code
NDF-RT N0000183362
Created by admin on Fri Dec 15 17:24:39 GMT 2023 , Edited by admin on Fri Dec 15 17:24:39 GMT 2023
Code System Code Type Description
RXCUI
1546429
Created by admin on Fri Dec 15 17:24:39 GMT 2023 , Edited by admin on Fri Dec 15 17:24:39 GMT 2023
PRIMARY RxNorm
CHEBI
49618
Created by admin on Fri Dec 15 17:24:39 GMT 2023 , Edited by admin on Fri Dec 15 17:24:39 GMT 2023
PRIMARY
DAILYMED
AZV954TZ9N
Created by admin on Fri Dec 15 17:24:39 GMT 2023 , Edited by admin on Fri Dec 15 17:24:39 GMT 2023
PRIMARY
DRUG BANK
DB14578
Created by admin on Fri Dec 15 17:24:39 GMT 2023 , Edited by admin on Fri Dec 15 17:24:39 GMT 2023
PRIMARY
CAS
22541-19-1
Created by admin on Fri Dec 15 17:24:39 GMT 2023 , Edited by admin on Fri Dec 15 17:24:39 GMT 2023
PRIMARY
PUBCHEM
168050
Created by admin on Fri Dec 15 17:24:39 GMT 2023 , Edited by admin on Fri Dec 15 17:24:39 GMT 2023
PRIMARY
EPA CompTox
DTXSID40892981
Created by admin on Fri Dec 15 17:24:39 GMT 2023 , Edited by admin on Fri Dec 15 17:24:39 GMT 2023
PRIMARY
FDA UNII
AZV954TZ9N
Created by admin on Fri Dec 15 17:24:39 GMT 2023 , Edited by admin on Fri Dec 15 17:24:39 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT